Search results
Showing 201 to 250 of 8175 results
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
The percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently...
Our board sets out our strategic priorities and policies. The day to day decision-making is the responsibility of our executive team . The...
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account...
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Intravascular lithotripsy for calcified arteries in peripheral arterial disease (IPG780)
Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.
View recommendations for IPG780Show all sections
Interventional procedures are used for diagnosis or treatment. They can include things like: making a cut or a hole to gain access to the inside of
NICE guidelines are evidence-based recommendations for health and care in England.
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) (TA940)
NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating generalised myasthenia gravis in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA940
NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA941
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.
Agenda and papers of the NICE public board meeting on 13 December 2023
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Our NICE talks podcasts bring you the real life experiences of people working within the NHS, public health and social care. Hear the stories behind...
Interventional Procedures Advisory Committee members
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
Melanie explains how the update to NICE’s quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
Middle meningeal artery embolisation for chronic subdural haematomas (IPG779)
Evidence-based recommendations on middle meningeal artery embolisation for chronic subdural haematomas. This involves injecting particles into the middle meningeal artery to block it.
View recommendations for IPG779Show all sections
This quality standard covers the period before, during and after a young person moves from children’s to adults’ services in all settings where transitions from children’s to adults’ health or social care services take place. It covers all young people (aged up to 25) using children’s health and social care services who are due to make the transition to adults’ services. This includes young people with mental health problems, disabilities and long-term, life-limiting or complex needs, rare diseases and those in secure settings or under the care of local authorities. It describes high-quality care in priority areas for improvement.
View quality statements for QS140Show all sections
Sections for QS140
- Quality statements
- Quality statement 1: Planning transition
- Quality statement 2: Coordinated transition plan
- Quality statement 3: Annual meeting
- Quality statement 4: Named worker
- Quality statement 5: Meeting a practitioner in adults' services
- Quality statement 6: Missed initial appointments after transfer to adults' services
- Update information
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
The percentage of patients with CVD in whom the last recorded LDL cholesterol level (measured in the preceding 12 months) is 2.0 mmol per litre or...
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home. People on a virtual ward are cared for by a multidisciplinary team
Agenda and papers of the NICE public board meeting on 21 September 2023
NICE is unable to make a recommendation on dupilumab (Dupixent) for treating eosinophilic oesophagitis in people 12 years and over. This is because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA938
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. This is because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA936
Details about how accessible NICE services are and who to contact for alternative versions of information
Our website is usually the quickest way to find the answer to a query. Take a look at: our guidance , advice , and quality standards who we are
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.
Show all sections
Sections for TA933
Health, public health and social care cost saving and improvement resources
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism (IPG778)
Evidence-based recommendations on percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. This involves removing the clot through a catheter inserted into a vein.
View recommendations for IPG778Show all sections
Find out more about the committee members by reading their biographies. Prof Stephen G O'Brien BSc (Hons) PhD MBChB FRCP MRCPath (chair) Biography
An independent advisory committee is responsible for making our interventional procedures recommendations. The committee includes both health...
NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA932
Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.
View recommendations for IPG777Show all sections
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.